Korean J Gastroenterol.  2017 Apr;69(4):263-265. 10.4166/kjg.2017.69.4.263.

Potassium-competitive Acid Blocker-based Therapy for Helicobacter pylori Eradication

• Bang CS
• Baik GH

• KMID: 2383407
• DOI: http://doi.org/10.4166/kjg.2017.69.4.263

Abstract

No abstract available.

MeSH Terms

Helicobacter pylori*
Helicobacter*

Reference

References

1. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016; 65:1439–1446.

2. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy. 1997; 17:22–37.

3. Parsons ME, Keeling DJ. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs. 2005; 14:411–421.

4. Mendlein J, Sachs G. Interaction of a K(+)-competitive inhibitor, a substituted imidazo[1,2a] pyridine, with the phospho- and de-phosphoenzyme forms of H+, K(+)-ATPase. J Biol Chem. 1990; 265:5030–5036.

5. Wurst W, Hartmann M. Current status of acid pump antagonists (reversible PPIs). Yale J Biol Med. 1996; 69:233–243.

6. Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]- N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011; 339:412–420.

7. Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-com-petitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010; 335:231–238.

8. Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potas-sium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011; 81:1145–1151.

9. Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 2011; 337:797–804.

10. Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+-ATPase. Aliment Pharmacol Ther. 2015; 42:1315–1326.

11. Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-com-petitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015; 42:685–695.

12. Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016; 43:240–251.

13. Sachs G, Shin JM, Munson K, et al. Review article: the control of gastric acid and helicobacter pylori eradication. Aliment Pharmacol Ther. 2000; 14:1383–1401.

14. Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potas-sium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015; 41:636–648.

15. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of helicobacter pylori infection. J Antimicrob Chemother. 1997; 39:5–12.

16. Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, DeBartolo ML, Schneck DW. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother. 1995; 39:2078–2083.